T Cell Proliferation Linked to CAR T Responses
T Cell Proliferation Linked to CAR T Responses
Comparing the cells of cancer patients who did and did not respond to the immunotherapy could reveal biomarkers to predict who should receive it in the first place.
T Cell Proliferation Linked to CAR T Responses
T Cell Proliferation Linked to CAR T Responses

Comparing the cells of cancer patients who did and did not respond to the immunotherapy could reveal biomarkers to predict who should receive it in the first place.

Comparing the cells of cancer patients who did and did not respond to the immunotherapy could reveal biomarkers to predict who should receive it in the first place.

CAR T cells
A Revised CAR T for Lymphoma Has Fewer Side Effects
A Revised CAR T for Lymphoma Has Fewer Side Effects
Kerry Grens | Apr 23, 2019
An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.
The Next Frontier of CAR T-Cell Therapy: Solid Tumors
The Next Frontier of CAR T-Cell Therapy: Solid Tumors
Kerry Grens | Apr 1, 2019
The technology has wowed the field by all but obliterating some patients’ blood cancers, but solid malignancies present new challenges.
Infographic: CAR-T Cells in Solid Versus Liquid Cancers
Infographic: CAR-T Cells in Solid Versus Liquid Cancers
Kerry Grens | Apr 1, 2019
Tumor accessibility, heterogeneity, and microenvironment vary between the two classes of malignancies.
CAR T Cells Treat Lupus in Mice
CAR T Cells Treat Lupus in Mice
Abby Olena | Mar 6, 2019
T cells modified to target disease-contributing B cells improved survival in two mouse models of the autoimmune disease.
<em>Nature&nbsp;</em>Retracts Paper on Delivery System for CAR T Immunotherapy
Nature Retracts Paper on Delivery System for CAR T Immunotherapy
Diana Kwon | Feb 20, 2019
The manuscript had amassed more than 50 comments about problematic figures and data on PubPeer.
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Catherine Offord | Jan 3, 2019
The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.
Two CAR T-Cell Therapies Greenlighted in Europe
Two CAR T-Cell Therapies Greenlighted in Europe
Jef Akst | Aug 28, 2018
Cancer treatments from Novartis and Gilead earn approval from EU regulators, but a first pass by the UK’s state-funded health service finds CAR T is too expensive. 
Natural Killer Cells Prove Effective as a CAR Therapy in Mice
Natural Killer Cells Prove Effective as a CAR Therapy in Mice
Katarina Zimmer | Jul 6, 2018
Stem-cell–derived natural killer cells engineered in a similar way to CAR-T cells may pave the way to “off the shelf” cancer therapies that aren’t patient-specific.
New Insights to Improve CAR T Cells’ Safety
New Insights to Improve CAR T Cells’ Safety
Vicki Brower | Jun 5, 2018
Drugs approved to treat rheumatoid arthritis block cytokines, the molecules responsible for severe side effects from the immunotherapy, and reduce symptoms in mice.